Etravirine: A second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection

Future HIV Therapy

Volumn 2, Issue 6, 2008, Pages 525-537

  Minuto, Joshua J ^a   Haubrich, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Entravirine; HIV; Intelence ; Non nucleoside reverse transcriptase inhibitor; TMC 125

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CARBAMAZEPINE; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; F 060; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; RIFAPENTINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TF 035; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; NAUSEA; PHARMACODYNAMICS; PHENOTYPE; POSTMARKETING SURVEILLANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 67149094850     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.6.525     Document Type: Article

References (42)

1. Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D: Time to AIDS from 1992 to 1999 in HIV-1 infected subjects with known dates of infection. J. Acquir. Immune Defic. Syndr. 30(1), 81-87 (2002).
2. Schneider MF, Gange SJ, Williams CM et al.: Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 19, 2009-2018 (2005).
3. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society - USA Panel. JAMA 300, 555-570 (2008).
4. Wainberg MA: HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 34, S2-S7 (2003).
5. Deeks SJ: Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26, S25-S33 (2001).
6. Cunningham CK, Chaix ML, Rekacewicz C et al.: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J. Infect. Dis. 186(2), 181-188 (2002).
7. Basavapathruni A, Vingerhoets J, De Bethune M et al.: Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 45, 7334-7340 (2006).
8. Pauwels, R: New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 4(5), 437-446 (2004).
9. Little SJ, Holte S, Routy JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347(6), 385-394 (2002).
10. Huang H, Daar ES, Sax PE et al.: The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection. HIV Medicine 9, 285-293 (2008).
11. Cane P, Chrystie I, Dunn D et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331, 1368 (2005).
12. Richman DD, Morton SC, Wrin T et al.: The prevalence of antiretroviral resistance in the United States. AIDS 18, 1393-1401 (2004).
13. Andries K, Azijn H, Thielemans T et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48(12), 4680-4686 (2004).
14. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL: Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J. Am. Chem. Soc. 125, 6016-6017 (2003).
15. Das K, Clark AD Jr, Lewi PJ et al.: Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47(10), 2550-2560 (2004).
16. Woodfall B, Vingerhoets J, Peeters M et al.: Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. Proceedings of the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, 12-16 November 2006.
17. Intelence™ (etravirine) tablets, package insert. Tibotec, Raritan, NJ, USA (2008).
18. Gazzard BG, Pozniak AL, Rosenbaum W et al.: An open-label assessment of TMC125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17, 49-54 (2003).
19. Kakuda TN, Scholler-Gyure M, Peeters M, et al.: Pharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-1 infected patients. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, Louisiana, USA, 7-9 April 2008.
20. Davis J, Scholler-Gyure M, Kakuda TN et al.: An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Presented at: 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007.
21. Vingerhoets J, Azijn H, Fransen E et al.: TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79(20), 12773-12782 (2005).
22. Scholler M, Hoetelmans R. Hects G et al.: Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, 28-30 April 2005.
23. Gruzdev B, Rakhmanova A, Doubovskaya E et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17, 2487-2494 (2003).
24. Sankatsing SUC, Weverling GJ, Peeters M et al.: TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 17, 2623-2627 (2003).
25. Weverling GJ, Lange JM, Jurriaans S et al.: Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 12, F177-F122 (1998).
26. Piscitelli S, Baede P, DeGier K, Van T Klooster G, Graham N: Pharmacokinetics of TMC 125 in HIV infected patients and healthy volunteers. Presented at: 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, USA, 11-13 April 2002.
27. Nadler JP, Berger DS, Blick G et al.: (TMC125-C223 Writing Group): efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 21(6), F1-F10 (2007).
28. Haubrich R, Cahn P, Grinsztejn B et al.: DUET-1: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1 patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
29. Madruga JV, Cahn P, Grinsztejm B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370(9581), 29-38 (2007).
30. Lazzarin A, Campbell T, Clotet B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370(9581), 39-48 (2007).
31. Hicks C, Cahn P, Leider J et al.: Pooled 24-week results of DUET-1 and -2: efficacy of TMC125 in treatment-experienced patients. Presented at: 45th Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 4-7 October 2007.
32. Geretti AM: Shifting paradigms: the resistance profile of etravirine. J. Antimicrob. Chemother. 62, 643-647 (2008).
33. Vingerhoets J, Buelens A, Peeters M et al.: Impact of baseline NNRTI mutations on the virologic response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Presented at: 16th International HIV Drug Resistance Workshop. Barbados, abstract 32 (2007).
34. Vingerhoets J, Peeters M, Azijn H et al.: An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Presented at: 17th International HIV Drug Resistance Workshop. Sitges, Spain, 10-14 June 2008.
35. Poveda E, Garrido C, De Mendoza C et al.: Prevalence of etravirine (TMC125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother. 60(6), 1409-1410 (2007).
36. Winters B, Villacian J, Van Craenenbroeck E, Bacheler L, Vingerhoets J, Peeters M: Development of Virco® type HIV-1 resistance analysis, including clinical cutoffs for TMC125 (Etravirine, ETR), a new NNRTI. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
37. Peeters M, Nijs S, Vingerhoets J et al.: Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled week 24 results of the DUET-1 and DUET-2 trials. Presented at: 17th International HIV Drug Resistance Workshop. Sitges, Spain, 10-14 June 2008.
38. Coakley E, Chappey C, Benhamida J et al.: Biological and clinical cutoff analyses for ETR in the PhenoSense HIV Assay. Presented at: 17th International HIV Drug Resistance Workshop. Sitges, Spain, 10-14 June 2008.
39. Haubrich R, Schechter M, Walmsley S, Peeters M, Janssens M, De Smedt G: TMC125 safety and tolerability in treatment-experienced, HIV infected patients - pooled DUET trial data. Presented at: 45th Meeting of the Infectious Diseases Society of America. San Diego, California, USA, 4-7 October 2007.
40. Di Perri G, Girard PM, Clumeck N, Peeters M, Janssens M, De Smedt G: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine;ETR) safety and tolerability in treatment-experienced, HIV-1 infected patients. Presented at: 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007.
41. Red Book. Pharmacy's Fundamental Reference, April 2008 Update. Thompson Healthcare, Montvale, NJ, USA, 511 (2008).
42. Bartlett JG, Gallant JE: 2007 Medical Management of HIV Infection. Johns Hopkins Medicine/Health Publishing Business Grou., Baltimore, MD, USA, 193, 272 (2007).